Page last updated: 2024-12-05

pirenoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pirenoxine is a synthetic compound with a complex structure. It was initially developed as a potential treatment for Parkinson's disease, but research has also explored its potential in other areas such as cognitive enhancement, anxiety reduction, and even cancer treatment. Its mode of action is believed to be through modulation of various neurotransmitter systems, particularly those involved in dopamine and serotonin signaling. However, the exact mechanisms are still under investigation. Despite promising preclinical results, pirenoxine has not yet been approved for any therapeutic use, and further research is needed to clarify its efficacy and safety profile.'

pirenoxine: structure given in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4846
CHEMBL ID1372341
CHEBI ID32013
SCHEMBL ID36173
SCHEMBL ID22360205
MeSH IDM0045705

Synonyms (41)

Synonym
PRX ,
D01100
pirenoxine (jp17/inn)
catalin-k (tn)
1043-21-6
pirenoxine
1,5-dioxo-4h-pyrido[3,2-a]phenoxazine-3-carboxylic acid
A800955
pirenoxina [spanish]
einecs 213-872-4
unii-27l0ep6izk
pirenoxine [inn:jan]
pirenoxinum
27l0ep6izk ,
5h-pyrido(3,2-a)phenoxazine-3-carboxylic acid, 1-hydroxy-5-oxo-
1-hydroxy-5-oxo-5h-pyrido(3,2-a)phenoxazine-3-carboxylic acid
pirenoxina
pirenoxinum [latin]
5h-pyrido[3,2-a]phenoxazine-3-carboxylicacid, 1-hydroxy-5-oxo-
CHEMBL1372341
catalin-k
FT-0603540
AKOS015888305
pirenoxine [who-dd]
pirenoxine [jan]
pirenoxine [mi]
pirenoxine [inn]
cataline
AM84317
SCHEMBL36173
DTXSID6048335
CHEBI:32013
4-hydroxy-12-oxo-12h-10-oxa-1,5-diazatetraphene-2-carboxylic acid
1-hydroxy-5-oxo-5h-pyrido[3,2-a]phenoxazine-3-carboxylic acid;1-hydroxy-5-oxo-5h-pyrido[3,2-a]phenoxazine-3-carboxylic acid
1-hydroxy-5-oxopyrido[3,2-a]phenoxazine-3-carboxylic acid
Q7197959
catalin
SCHEMBL22360205
BS-42378
CS-0028168
HY-108296

Research Excerpts

Bioavailability

Organic-inorganic hybrid nanocomposites including layered double hydroxides (LDH) and chitosan derivatives were designed. Prolonged precorneal retention, better corneal permeability and enhanced ocular bioavailability of the model drug pirenoxine sodium were observed.

ExcerptReferenceRelevance
"To improve the ocular bioavailability of the model drug of pirenoxine sodium (PRN), organic-inorganic hybrid nanocomposites including layered double hydroxides (LDH) and chitosan derivatives (chitosan-glutathione (CG), chitosan-glutathione-valine (CG-V) and chitosan-glutathione-valine-valine (CG-VV)) were designed and characterized."( Multifunctional properties of organic-inorganic hybrid nanocomposites based on chitosan derivatives and layered double hydroxides for ocular drug delivery.
Cao, F; Chi, H; Xu, T; Zhang, J, 2016
)
0.68
" Prolonged precorneal retention, better corneal permeability and enhanced ocular bioavailability of the model drug pirenoxine sodium were observed."( Multifunctional properties of organic-inorganic hybrid nanocomposites based on chitosan derivatives and layered double hydroxides for ocular drug delivery.
Cao, F; Chi, H; Xu, T; Zhang, J, 2016
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (28.13)18.7374
1990's7 (21.88)18.2507
2000's5 (15.63)29.6817
2010's9 (28.13)24.3611
2020's2 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.14 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index77.25 (26.88)
Search Engine Supply Index2.74 (0.95)

This Compound (40.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (11.76%)5.53%
Reviews1 (2.94%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other28 (82.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]